指南与共识核素与放射性配体治疗

钇-90树脂微球选择性内放射治疗原发性与转移性肝病的个体化国际推荐

International recommendations for personalised selective internal radiation therapy of primary and metastatic liver diseases with yttrium-90 resin microspheres.
指南 / 共识 · Eur J Nucl Med Mol Imaging · 2021-01-12

推荐涵盖多学科团队决策、影像评估、个体化剂量学处方、安全剂量阈值及治疗后验证与剂量学,并定义了推荐强度。

要点

  • 多学科团队应确定治疗策略与治疗意图(强一致)。
  • 推荐使用CT三维成像、锥形束CT血管造影及99mTc-MAA SPECT/CT评估沉积与计算活度。
  • 推荐采用个体化剂量学(分区模型和/或体素)进行活度处方,非肿瘤肝平均吸收剂量≤40 Gy视为安全。

核心结论

  • 鼓励从业者努力采纳这些关于钇-90树脂微球SIRT的推荐。

研究设计与样本

  • 由23名国际专家组成的指导委员会基于文献检索和43名顶级专家匿名完成的61题问卷制定推荐,问卷经指导委员会验证。
  • 面对面会议中展示并讨论问卷结果,据此推导推荐并定义一致程度:强一致≥80%,中等一致50%-79%,无一致≤49%。

主要发现

  • 推荐3D CT成像、锥形束CT血管造影(如有)及99mTc-MAA SPECT/CT用于肝外/肝内沉积评估、治疗野定义和90Y树脂微球所需活度计算(中等/强一致)。
  • 推荐个体化剂量学(分区模型和/或体素)用于全肝或选择性、非消融或消融SIRT的活度处方(强一致)。
  • 非肿瘤肝平均吸收剂量≤40 Gy被视为安全(强一致)。
  • 肝细胞癌、结直肠癌肝转移和胆管癌推荐肿瘤最小平均吸收剂量100-120 Gy(中等/强一致)。

关键数值与推荐

  • 一致程度定义:强一致≥80%,中等一致50%-79%,无一致≤49%。
  • 非肿瘤肝平均吸收剂量≤40 Gy视为安全(强一致)。
  • 肝细胞癌、结直肠癌肝转移和胆管癌的肿瘤最小平均吸收剂量推荐100-120 Gy(中等/强一致)。

临床怎么用

  • 多学科团队应确定治疗策略与治疗意图。
  • 使用CT三维成像、锥形束CT血管造影(如有)和99mTc-MAA SPECT/CT进行沉积评估、治疗野定义和活度计算。
  • 采用个体化剂量学(分区模型和/或体素)进行活度处方,并确保非肿瘤肝平均吸收剂量≤40 Gy。
  • 对肝细胞癌、结直肠癌肝转移和胆管癌,肿瘤最小平均吸收剂量目标为100-120 Gy。
  • 治疗后使用90Y-PET/CT进行验证并开展治疗后剂量学。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: A multidisciplinary expert panel convened to formulate state-of-the-art recommendations for optimisation of selective internal radiation therapy (SIRT) with yttrium-90 (90Y)-resin microspheres. METHODS: A steering committee of 23 international experts representing all participating specialties formulated recommendations for SIRT with 90Y-resin microspheres activity prescription and post-treatment dosimetry, based on literature searches and the responses to a 61-question survey that was completed by 43 leading experts (including the steering committee members). The survey was validated by the steering committee and completed anonymously. In a face-to-face meeting, the results of the survey were presented and discussed. Recommendations were derived and level of agreement defined (strong agreement ≥ 80%, moderate agreement 50%-79%, no agreement ≤ 49%). RESULTS: Forty-seven recommendations were established, including guidance such as a multidisciplinary team should define treatment strategy and therapeutic intent (strong agreement); 3D imaging with CT and an angiography with cone-beam-CT, if available, and 99mTc-MAA SPECT/CT are recommended for extrahepatic/intrahepatic deposition assessment, treatment field definition and calculation of the 90Y-resin microspheres activity needed (moderate/strong agreement). A personalised approach, using dosimetry (partition model and/or voxel-based) is recommended for activity prescription, when either whole liver or selective, non-ablative or ablative SIRT is planned (strong agreement). A mean absorbed dose to non-tumoural liver of 40 Gy or less is considered safe (strong agreement). A minimum mean target-absorbed dose to tumour of 100-120 Gy is recommended for hepatocellular carcinoma, liver metastatic colorectal cancer and cholangiocarcinoma (moderate/strong agreement). Post-SIRT imaging for treatment verification with 90Y-PET/CT is recommended (strong agreement). Post-SIRT dosimetry is also recommended (strong agreement). CONCLUSION: Practitioners are encouraged to work towards adoption of these recommendations.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Levillain H, Bagni O, Deroose CM, et al. International recommendations for personalised selective internal radiation therapy of primary and metastatic liver diseases with yttrium-90 resin microspheres. Eur J Nucl Med Mol Imaging. 2021. PMID: 33433699. doi:10.1007/s00259-020-05163-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。